Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

European DIPG Registry

Childhood Oncology Group (DCOG), a National Paediatric Haematology[Oncology Society (NaPHOS)  member of SIOPE. DCOG is mandated by the Executive Committee of the SIOPE DIPG Network to act as a  legal entity on its behalf in matters concerning the DIPG Registry. The Parties acknowledge and agree that  ...

MRI Guided Focused Ultrasound: Targeted Drug Delivery in Diffuse Intrinsic ...

Hypothesis & Anticipated Results Diffuse Intrinsic Pontine Glioma, (DIPG) is a fatal cancer and the leading cause of death from  brain tumours in young children. Despite numerous existing chemotherapeutic agents and  promising new molecular therapies, one overriding challenge remains: to overcome the blood  brain barrier (BBB) and ...

Sequential phase I studies of nivolumab monotherapy and nivolumab in ...

Developing effective treatments for pediatric CNS tumors arguably represents the major remaining unmet need in pediatric oncology.  We propose a phase I study of nivolumab and then another phase I study of the combination of ipilimumab and nivolumab in children with recurrent/refractory brain tumors. Ipilimumab ...

International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) ...

Diffuse intrinsic pontine gliomas (DIPG) are the most common brainstem tumors in children, representing approximately 75-80% of all pediatric brainstem tumors. Approximately 200-300 patients are diagnosed with DIPG North America and a similar number in Europe.  DIPG accounts for 10-15% of all new pediatric brain tumor diagnoses and is ...

Photodynamic therapy of diffuse intrinsic pontine glioma in combination with ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brain tumor and a leading cause of pediatric brain tumor-related mortality. Even with treatment, the median survival of patients with DIPG is 9–11 months. Despite a number of clinical trials, no treatments have proven more effective than radiation therapy (RT) for ...

Targeting Group 4 medulloblastoma via Musashi1-cell cycle inhibition

Despite recent progress in medulloblastoma treatment, two main problems remain. High risk groups 3 and 4 medulloblastoma patients still show a high rate of mortality. Even in the case of success, patients are frequently left with devastating neurocognitive and other sequelae. Therefore, more effective and less aggressive therapies are still in demand. ...